Scrivo, R. et al. 2022. Secukinumab Treatment in Patients with Spondyloarthritis and Concomitant Demyelinating Disease: Rationale of IL-17 Inhibition and Clinical Outcome. Archives of Clinical and Medical Case Reports. 6, 5 (Oct. 2022), 660–668.